Clinical Trial Update: A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ASP1650, a monoclonal antibody targeting Claudin 6, in men with incurable platinum-refractory germ cell tumors has completed and result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Germ Cell Tumor

Drugs mentioned

• ASP1650

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Incurable Platinum Refractory Germ Cell Tumors, Tumors | Phase 2 | Status: COMPLETED | Results posted: 2021-11-10